Investing $24 billion to have prototype vaccines ready for each of the 26 known viral families is a strategic and forward-thinking move. The lessons from the COVID-19 pandemic have shown us the immense value of preparedness. This investment could not only save countless lives but also stabilize economies and prevent future global disruptions.